{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PK+Testing",
    "query": {
      "intervention": "PK Testing"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 87,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PK+Testing&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T05:56:02.580Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04280289",
      "title": "CBD Cannabis Extract: Pharmacokinetic Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "cannabidiol extract",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Mississippi, Oxford",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-02-01",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "University, Mississippi",
      "locations": [
        {
          "city": "University",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04280289"
    },
    {
      "nct_id": "NCT01453023",
      "title": "Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate/Vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "5 Years to 11 Years"
      },
      "enrollment_count": 26,
      "start_date": "2011-10",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "Huntington Beach, California",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01453023"
    },
    {
      "nct_id": "NCT04528290",
      "title": "A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2020-10-07",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04528290"
    },
    {
      "nct_id": "NCT03370718",
      "title": "Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Carcinoma in the Adrenal Cortex",
        "Stage III Adrenal Cortex Carcinoma AJCC v8",
        "Stage IV Adrenal Cortex Carcinoma AJCC v8",
        "Unresectable Adrenal Cortex Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        },
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-02-26",
      "completion_date": "2024-01-12",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03370718"
    },
    {
      "nct_id": "NCT01602887",
      "title": "Relative Bioavailability Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PD-0332991",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2012-05",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2012-11-12",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01602887"
    },
    {
      "nct_id": "NCT00258440",
      "title": "Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anemia",
        "Fatigue",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "Weekly procrit dosing",
          "type": "DRUG"
        },
        {
          "name": "Interval Dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2003-05",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00258440"
    },
    {
      "nct_id": "NCT02276989",
      "title": "Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Compliance",
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "Quinine",
          "type": "DRUG"
        },
        {
          "name": "Riboflavin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-12",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2017-02-10",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02276989"
    },
    {
      "nct_id": "NCT03654547",
      "title": "Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TT-00420",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TransThera Sciences (Nanjing), Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 48,
      "start_date": "2019-01-08",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-07-24",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03654547"
    },
    {
      "nct_id": "NCT03199339",
      "title": "A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis",
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "TBA-7371",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 74,
      "start_date": "2017-08-29",
      "completion_date": "2018-07-08",
      "has_results": false,
      "last_update_posted_date": "2018-10-17",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03199339"
    },
    {
      "nct_id": "NCT01364805",
      "title": "New Treatment Option for Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Intravenous Vitamin C",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeanne Drisko, MD, CNS, FACN",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2011-04",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2018-06-19",
      "last_synced_at": "2026-09-09T05:56:02.580Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01364805"
    }
  ]
}